Vadodara, India, July 8, 2024 – The promoters of Sudeep Pharma Private Limited have completed the acquisition of shares from their joint venture partners, JRS PHARMA, regaining 100% ownership of the company. This strategic move represents an important step in Sudeep Pharma's continued growth and development, allowing the company to pursue its vision.
The promoters of Sudeep Pharma, Mr. Sujit Bhayani & Family, formed a joint venture in 2015 with JRS Pharma. Combining JRS Pharma's excipient expertise with Sudeep Pharma's technological advancements and strong manufacturing capabilities has resulted in significant growth and valuable cooperation over the past nine years.
Sudeep Pharma remains dedicated to offering cutting-edge pharmaceutical solutions, maintaining the highest quality standards and ensuring continuous customer satisfaction. The company is set to accelerate its research and development initiatives, expand its product portfolio and pursue new opportunities to lead the global market.
Both Sudeep Pharma and JRS Pharma assure all stakeholders that this transaction will not have any impact on current operations or product availability. Customers can expect to receive the same exceptional levels of service and product quality that both companies have consistently provided.
About Sudeep Pharma Private Limited:
Founded in 1989, Sudeep Pharma Group is a leading manufacturer of specialty ingredients for the pharmaceutical, nutraceutical and food industries. Starting with one excipient manufacturing plant, the group has expanded significantly and now operates six manufacturing plants worldwide. Sudeep Pharma offers a comprehensive product portfolio including pharmaceutical excipients, mineral actives and specialty ingredients designed for the nutraceutical and food industries. The company prioritizes leveraging its technological experience to innovate solutions for sustained growth.
Committed to setting new benchmarks in the healthcare industry, Sudeep Pharma intends to continue expanding its business both organically and inorganically. The company is actively enhancing its presence in India, US and Europe through its subsidiaries, maintaining a strong focus on quality, integrity and customer satisfaction.
(Disclaimer: The above press release is provided by HT Syndication and will not assume any editorial responsibility for this content.)
The promoters of Sudeep Pharma, Mr. Sujit Bhayani & Family, formed a joint venture in 2015 with JRS Pharma. Combining JRS Pharma's excipient expertise with Sudeep Pharma's technological advancements and strong manufacturing capabilities has resulted in significant growth and valuable cooperation over the past nine years.
Sudeep Pharma remains dedicated to offering cutting-edge pharmaceutical solutions, maintaining the highest quality standards and ensuring continuous customer satisfaction. The company is set to accelerate its research and development initiatives, expand its product portfolio and pursue new opportunities to lead the global market.
Both Sudeep Pharma and JRS Pharma assure all stakeholders that this transaction will not have any impact on current operations or product availability. Customers can expect to receive the same exceptional levels of service and product quality that both companies have consistently provided.
About Sudeep Pharma Private Limited:
Founded in 1989, Sudeep Pharma Group is a leading manufacturer of specialty ingredients for the pharmaceutical, nutraceutical and food industries. Starting with one excipient manufacturing plant, the group has expanded significantly and now operates six manufacturing plants worldwide. Sudeep Pharma offers a comprehensive product portfolio including pharmaceutical excipients, mineral actives and specialty ingredients designed for the nutraceutical and food industries. The company prioritizes leveraging its technological experience to innovate solutions for sustained growth.
Committed to setting new benchmarks in the healthcare industry, Sudeep Pharma intends to continue expanding its business both organically and inorganically. The company is actively enhancing its presence in India, US and Europe through its subsidiaries, maintaining a strong focus on quality, integrity and customer satisfaction.
(Disclaimer: The above press release is provided by HT Syndication and will not assume any editorial responsibility for this content.)
